Vertex Pharmaceuticals, Inc. (VRTX)
541.69
-5.86
(-1.07%)
USD |
NASDAQ |
Aug 28, 14:20
Vertex Pharmaceuticals Cash from Operations (Quarterly) : 1.125B for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.125B |
| March 31, 2026 | 1.428B |
| December 31, 2025 | 498.00M |
| September 30, 2025 | 1.241B |
| June 30, 2025 | 1.073B |
| March 31, 2025 | 818.90M |
| December 31, 2024 | 584.60M |
| September 30, 2024 | 1.370B |
| June 30, 2024 | -3.754B |
| March 31, 2024 | 1.307B |
| December 31, 2023 | 234.60M |
| September 30, 2023 | 1.268B |
| June 30, 2023 | 1.134B |
| March 31, 2023 | 899.90M |
| December 31, 2022 | 1.078B |
| September 30, 2022 | 955.50M |
| June 30, 2022 | 1.140B |
| March 31, 2022 | 956.20M |
| December 31, 2021 | 994.99M |
| September 30, 2021 | 927.22M |
| June 30, 2021 | -199.77M |
| March 31, 2021 | 921.06M |
| December 31, 2020 | 491.53M |
| September 30, 2020 | 907.75M |
| June 30, 2020 | 1.039B |
| Date | Value |
|---|---|
| March 31, 2020 | 815.70M |
| December 31, 2019 | 446.01M |
| September 30, 2019 | 334.79M |
| June 30, 2019 | 463.75M |
| March 31, 2019 | 324.78M |
| December 31, 2018 | 314.58M |
| September 30, 2018 | 381.35M |
| June 30, 2018 | 321.70M |
| March 31, 2018 | 252.66M |
| December 31, 2017 | 227.51M |
| September 30, 2017 | 170.09M |
| June 30, 2017 | 181.65M |
| March 31, 2017 | 265.69M |
| December 31, 2016 | 144.72M |
| September 30, 2016 | 65.66M |
| June 30, 2016 | 40.86M |
| March 31, 2016 | -15.14M |
| December 31, 2015 | -16.01M |
| September 30, 2015 | -47.02M |
| June 30, 2015 | -95.21M |
| March 31, 2015 | -207.18M |
| December 31, 2014 | -121.87M |
| September 30, 2014 | -87.65M |
| June 30, 2014 | -127.92M |
| March 31, 2014 | -175.76M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 3.573B |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| Sionna Therapeutics, Inc. | -22.22M |
| Biogen, Inc. | 448.90M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -45.80M |
| Cash from Financing (Quarterly) | -426.70M |
| Free Cash Flow | 3.796B |
| Free Cash Flow Per Share (Quarterly) | 3.970 |
| Free Cash Flow to Equity (Quarterly) | 1.022B |
| Free Cash Flow to Firm (Quarterly) | 1.013B |
| Free Cash Flow Yield | 2.73% |